(2010) Polysialylated neuropilin-2 enhances human dendritic cell migration through the basic C-terminal region of CCL21 Glycobiology . 20 (9):1139-46. Schulz, E.C. , Dickmanns, A., Urlaub, H., Schmitt [...] Weinhold, B.; Gerardy-Schahn , R.; von Itzstein, M.; Ficner, R.; Münster-Kühnel, A.-K., (2009) A C-terminal phosphatase module conserved in vertebrate CMP-sialic acid synthetases provides a tetramerization
M, Welte T, Martinez-Delgado B, Janciauskiene S. A Novel Mouse Monoclonal Antibody C42 against C-Terminal Peptide of Alpha-1-Antitrypsin. Int J Mol Sci. 2021 Feb 21;22(4):2141. doi: 10.3390/ijms22042141
Liu, Xiaofei , Norbert Benda, Clemens Mittmann, and Armin Koch . 2024. “Combining Recurrent and Terminal Events Into a Composite Endpoint May Be Problematic.” Statistics in Biopharmaceutical Research 1–8
Liu, Xiaofei, Norbert Benda, Clemens Mittmann, and Armin Koch . 2024. “Combining Recurrent and Terminal Events Into a Composite Endpoint May Be Problematic.” Statistics in Biopharmaceutical Research 1–8 [...] Liu, Xiaofei , Norbert Benda, Clemens Mittmann, and Armin Koch. 2024. “Combining Recurrent and Terminal Events Into a Composite Endpoint May Be Problematic.” Statistics in Biopharmaceutical Research 1–8
Biology, LMU, Germany Graduation 8th July 2022 Cornelius Angela Research Topic: Binding of the N-terminal region of the large tegument protein HSV1-pUL36 to the host nucleoporin Nup358 C-terminus might
Genomics and Medicine, and the Hong Kong Hub of Paediatric Excellence (HK HOPE): ‘Cardiomyocyte terminal differentiation, de-differentiation, and the centrosome’ 21.04.2021 - REBIRTH Kolloquium (1 pm s
Moreno R, Maine GN, Kracht M, Schmitz ML, Burstein E. Oncogene. 2011; Publisher's page c-Jun N-terminal kinase phosphorylates DCP1a to control formation of P bodies. Rzeczkowski K, Beuerlein K, Müller
Gerold, G., Beule, D., and Goffinet, C. 2023. Pharmacological inhibition of bromodomain and extra-terminal proteins induces an NRF-2-mediated antiviral state that is subverted by SARS-CoV-2 infection. PLoS
Berlin, Mai 2005. Kuch C, Dierks ML, Scheibler F, Stoffel MP, Pfaff H. Der Wunsch von Patienten mit termina-ler Niereninsuffizienz, sich an Therapieentscheidungen zu beteiligen. 3. Kongress des För-derschwerpunktes
Sehr geehrte Patientinnen und Patienten, wenn die Nieren endgültig ihre Funktion verlieren, müssen Sie dauerhaft mit einem Verfahren des künstlichen Organersatzes (Hämodialyse, Hämofiltration, Periton